Formycon AG / DE000A1EWVY8
07.08.2024 - 06:50:07Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
| Formycon AG / Key word(s): Half Year Results/Conference 07.08.2024 / 06:50 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // August 7, 2024 Planegg-Martinsried, Germany – Formycon AG (FWB: FYB) today announced details for the financial and earnings conference call for the first half of the 2024 fiscal year on August 13, 2024. The Management Board will discuss the company's development, key financial figures, and provide an outlook for the second half of 2024. The conference call, which will be broadcast live on the internet, will take place on August 13, 2024, at 3:00 PM (CEST) in English. To participate, please register at: https://webcast.meetyoo.de/reg/T7S30CRURfic After registration, participants will receive a confirmation email with individual dial-in data. The presentation and audio broadcast can be accessed via the following webcast link: https://www.webcast-eqs.com/formycon-2024-h1 After a brief presentation, the Management Board will be available for analysts' questions. The conference call will be recorded and can subsequently be accessed via the Formycon website at: https://www.formycon.com/en/investor-relations/facts-figures/ Formycon in Dialogue Additionally, representatives of the Management Board will participate in the following international investor conferences in the coming weeks: August 21-22, 2024: HIT – Hamburger Investorentag Enno Spillner (CFO) Hamburg, Germany September 9-11, 2024: H.C. Wainwright Annual Global Investment Conference Enno Spillner (CFO) New York, USA September 19, 2024: Pareto Securities’ 15th Annual Healthcare Conference Dr. Stefan Glombitza (CEO) Stockholm, Sweden September 23-25, 2024: Berenberg and Goldman Sachs German Corporate Conference Dr. Stefan Glombitza (CEO) & Enno Spillner (CFO) Munich, Germany For the latest schedule of Formycon's events, please visit: https://www.formycon.com/en/investor-relations/calendar/ About Formycon: Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/Ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA, and FYB203/Aflibercept-mrbb has been approved by the FDA. Four additional biosimilar candidates, including FYB206/Pembrolizumab, are currently in development. Through its biosimilars, Formycon makes a significant contribution to enabling as many patients as possible to access highly effective and affordable medications. Formycon AG is headquartered in Munich and is listed on the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com About Biosimilars: Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare providers. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030. Contact: Sabrina Müller, Director Investor Relations & Corporate Communications, Formycon AG Fraunhoferstr. 15 82152 Planegg-Martinsried Germany Tel.: +49 (0) 89 - 86 46 67 149 Fax: + 49 (0) 89 - 86 46 67 110 Sabrina.Mueller@formycon.com Disclaimer: This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States. 07.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Formycon AG |
| Fraunhoferstraße 15 | |
| 82152 Planegg-Martinsried | |
| Germany | |
| Phone: | 089 864667 100 |
| Fax: | 089 864667 110 |
| Internet: | www.formycon.com |
| ISIN: | DE000A1EWVY8 |
| WKN: | A1EWVY |
| Indices: | Scale 30 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1962209 |
| End of News | EQS News Service |
| |
